Vericel Corp
Vericel Corp is a biotechnology company that develops and commercializes cellular therapies, generating revenue through the sale of specialized medical products.
Business. Vericel Corp (VCEL.O) is a biotechnology company headquartered in the United States that operates within the Health Care sector. The firm is primarily listed on the NASDAQ stock exchange under the ticker symbol VCEL.O. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a biotechnology entity engaged in product sales.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vericel Corp (VCEL.O) is a biotechnology company headquartered in the United States that operates within the Health Care sector. The firm is primarily listed on the NASDAQ stock exchange under the ticker symbol VCEL.O. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a biotechnology entity engaged in product sales.
Vericel Corp maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $100.1 million in cash and equivalents against total liabilities of $133.3 million, providing a solid liquidity buffer. Operating cash flow stands at $51.9 million, which comfortably covers capital expenditures of $27.2 million, indicating positive free cash flow generation. The company trades at a price-to-book ratio of 6.66 and an EV/EBITDA of 143.34, reflecting a premium valuation relative to its asset base and earnings before interest, taxes, depreciation, and amortization.
Profitability metrics show a gross profit of $205.6 million on revenue of $276.3 million, yielding a gross margin of approximately 74.4%. However, operating income is $11.0 million, and net income is $16.5 million, resulting in a return on equity (ROE) of 6.05% and a return on assets (ROA) of 4.4%. These returns are modest, suggesting that while the core product has high margins, operating expenses significantly compress net profitability. The price-to-earnings ratio of 110.0 indicates that investors are pricing in significant future growth expectations rather than current earnings power.
Revenue concentration and segment details are not explicitly provided in the available data, but the high gross margin suggests a focused product portfolio with strong pricing power. The company’s geographic exposure is not detailed in the current snapshot, limiting the ability to assess regional risk factors. The absence of segment data prevents a granular analysis of revenue drivers, but the overall financial health appears stable with consistent cash flow generation.
Growth trajectory analysis is limited by the absence of historical period data in the current input. Without multi-year revenue or net income trends, it is not possible to quantify the year-over-year growth rate or assess the sustainability of recent performance. The current revenue base of $276.3 million serves as the baseline for future projections, but historical context is required to validate growth assumptions.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company’s debt-free status mitigates credit risk, and the substantial cash position provides operational flexibility. The primary risk appears to be valuation-related, given the high P/E and EV/EBITDA multiples, which leave little room for execution errors or growth deceleration.
Recent IR observations show a mean analyst price target of $57.14, with a median target of $55.00, implying potential upside from the current market price of $46.64. The mean recommendation is 1.75, driven by three strong-buy and four buy ratings, indicating positive sentiment among analysts. The high price target of $70.00 and low of $46.00 suggest a wide range of expectations, but the consensus leans towards growth.
- Vericel Corp operates with a debt-free balance sheet and $100.1 million in cash, ensuring strong liquidity.
- High gross margins of ~74.4% are offset by operating expenses, resulting in a modest ROE of 6.05%.
- Valuation multiples are elevated, with a P/E of 110.0 and EV/EBITDA of 143.34, reflecting high growth expectations.
- Analyst sentiment is positive, with a mean recommendation of 1.75 and a mean price target of $57.14.
- No immediate liquidity or dilution risks are identified, supporting financial stability.
Bull / Bear case
Generated · model-assistedRevenue grew 16.5% year-over-year to $276.3 million in fiscal 2026, demonstrating strong top-line expansion momentum.
Net income surged 59.4% to $16.5 million in fiscal 2026, reflecting significant improvement in overall profitability.
Operating income increased 144.4% to $11.0 million in fiscal 2026, indicating substantial gains in core operational efficiency.
Free cash flow turned positive at $0.9 million in fiscal 2026, marking a critical shift from previous cash burn.
Long-term debt increased to $2.0 million in fiscal 2026, up from $0.7 million in the prior year, raising leverage concerns.
Return on assets of 4.4% suggests that asset utilization efficiency may lag behind revenue growth rates.
Debt-to-equity ratio of 0.376 indicates increasing reliance on debt financing compared to previous periods of minimal debt.
In focus — financials by report
Revenue $68.4M, +30,1% YoY; Operating income +37,0% YoY.
- ▍Revenue $68.4M, +30,1% YoY
- ▍Operating income +37,0% YoY
- ▍Net income +44,0% YoY
- ▍Free cash flow +81,3% YoY
- ▍Net margin -9.2%
Revenue $92.9M, +23,3% YoY; Operating income +21,3% YoY.
- ▍Revenue $92.9M, +23,3% YoY
- ▍Operating income +21,3% YoY
- ▍Net income +17,4% YoY
- ▍Free cash flow +221,1% YoY
- ▍Net margin 25.0%
Revenue $67.5M, +16,6% YoY; Operating income +240,0% YoY.
- ▍Revenue $67.5M, +16,6% YoY
- ▍Operating income +240,0% YoY
- ▍Net income +663,1% YoY
- ▍Free cash flow +128,8% YoY
- ▍Net margin 7.5%
Revenue $63.2M, +20,1% YoY; Operating income +66,4% YoY.
- ▍Revenue $63.2M, +20,1% YoY
- ▍Operating income +66,4% YoY
- ▍Net income +88,2% YoY
- ▍Free cash flow +71,1% YoY
- ▍Net margin -0.9%
Revenue $52.6M; Operating income -$12.8M.
- ▍Revenue $52.6M
- ▍Operating income -$12.8M
- ▍Net margin -21.4%
Revenue $75.4M; Operating income $18.5M.
- ▍Revenue $75.4M
- ▍Operating income $18.5M
- ▍Net margin 26.3%
Revenue $57.9M; Operating income -$2.5M.
- ▍Revenue $57.9M
- ▍Operating income -$2.5M
- ▍Net margin -1.6%
Revenue $52.7M; Operating income -$6.0M.
- ▍Revenue $52.7M
- ▍Operating income -$6.0M
- ▍Net margin -8.9%
Revenue $276.3M, +16,4% YoY; Operating income +144,4% YoY.
- ▍Revenue $276.3M, +16,4% YoY
- ▍Operating income +144,4% YoY
- ▍Net income +59,4% YoY
- ▍Free cash flow +101,9% YoY
- ▍Net margin 6.0%
Revenue $237.2M, +20,1% YoY; Operating income +169,9% YoY.
- ▍Revenue $237.2M, +20,1% YoY
- ▍Operating income +169,9% YoY
- ▍Net income +425,6% YoY
- ▍Free cash flow −84,6% YoY
- ▍Net margin 4.4%
Revenue $197.5M, +20,2% YoY; Operating income +62,1% YoY.
- ▍Revenue $197.5M, +20,2% YoY
- ▍Operating income +62,1% YoY
- ▍Net income +81,0% YoY
- ▍Free cash flow −28,4% YoY
- ▍Net margin -1.6%
Revenue $164.4M, +5,2% YoY; Operating income −117,2% YoY.
- ▍Revenue $164.4M, +5,2% YoY
- ▍Operating income −117,2% YoY
- ▍Net income −123,7% YoY
- ▍Free cash flow −63,9% YoY
- ▍Net margin -10.2%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,47 |
| Revenue | —no estimate | —no estimate | 332,2M USD |
| Operating income | —no estimate | —no estimate | 24,0M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $34,90exercise · 2026-07-30
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 2 500 @ $29,82exercise · 2026-07-30
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 500 @ $29,82exercise · 2026-07-30
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $16,25exercise · 2026-06-26
- Principal Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 2 500 @ $29,82exercise · 2026-06-26
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 5 000 @ $29,82exercise · 2026-06-26
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $16,25exercise · 2026-06-18
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 10 000 @ $16,66exercise · 2026-06-18
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 4 375 @ $16,66exercise · 2026-06-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 3 500 @ $2,63exercise · 2026-05-13
- Director · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200exercise · 2026-04-29
- Director · Restricted Stock Unit → Common StockAcquired 3 200grant · 2026-04-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 8 000 @ $33,43grant · 2026-04-29
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- VERICEL CORPORATION Market data — financials · 2026-07-18
- Vericel Corp Market data — analyst estimates · 2026-07-18
- Vericel Corp Market data — ESG · 2026-07-18
- Vericel Corp HA canonical relationships · 2026-07-18
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,01 %$370M
- Investment Managers · as of 2026-03-310,01 %$27M
- Investment Managers · as of 2026-03-310,00 %$8M
- Brokerage Firms · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$101M
- Investment Managers · as of 2026-03-310,00 %$24M
- Investment Managers · as of 2026-03-310,00 %$40M
- Investment Managers · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$7M
- Investment Managers · as of 2025-12-310,00 %$129M
- Investment Managers · as of 2026-03-310,00 %$9M
- Institutional Investor · as of 2026-03-310,00 %$9M
- Institutional Investor · as of 2026-03-310,00 %$7M
- Funds · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$3M
Leadership
- Dominick C ColangeloPresident, Chief Executive Officer, Director
Insider activity
- Principal Accounting Officer · Common StockSold 2 500 @ $48,90$122K · 2026-07-30
- Principal Accounting Officer · Common StockOther 500 @ $29,82$15K · 2026-07-30
- Principal Accounting Officer · Common StockSold 500 @ $48,90$24K · 2026-07-30
- Principal Accounting Officer · Common StockOther 1 500 @ $34,90$52K · 2026-07-30
- Principal Accounting Officer · Common StockOther 2 500 @ $29,82$75K · 2026-07-30
- Principal Accounting Officer · Common StockSold 1 500 @ $48,90$73K · 2026-07-30
- Principal Accounting Officer · Common StockSold 2 500 @ $44,90$112K · 2026-06-26
- Chief Financial Officer · Common StockSold 5 000 @ $44,75$224K · 2026-06-26
- Chief Medical Officer · Common StockOther 5 000 @ $29,82$149K · 2026-06-26
- Chief Medical Officer · Common StockSold 5 000 @ $45,00$225K · 2026-06-26
- Chief Legal Officer · Common StockOther 15 000 @ $16,25$244K · 2026-06-26
- Chief Legal Officer · Common StockSold 15 000 @ $45,64$685K · 2026-06-26
- Principal Accounting Officer · Common StockSold 232 @ $44,90$10K · 2026-06-26
- Principal Accounting Officer · Common StockOther 2 500 @ $29,82$75K · 2026-06-26
- Chief Legal Officer · Common StockOther 15 000 @ $16,25$244K · 2026-06-18
- Chief Operating Officer · Common StockSold 10 000 @ $40,24$402K · 2026-06-18
- Chief Operating Officer · Common StockOther 10 000 @ $16,66$167K · 2026-06-18
- Chief Legal Officer · Common StockSold 15 000 @ $40,21$603K · 2026-06-18
- Chief Medical Officer · Common StockOther 4 375 @ $16,66$73K · 2026-06-02
- Chief Medical Officer · Common StockSold 4 375 @ $35,00$153K · 2026-06-02
- Director · Common StockSold 3 500 @ $32,83$115K · 2026-05-13
- Director · Common StockSold 3 500 @ $32,82$115K · 2026-05-13
- Director · Common StockOther 3 500 @ $13,05$46K · 2026-05-13
- Director · Common StockOther 3 500 @ $2,63$9K · 2026-05-13
- Director · Common StockSold 7 500 @ $32,64$245K · 2026-05-11
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current assets (annual): USD 247.44MUnknown
- R&D expense (annual): USD 27.56MUnknown
- Current liabilities (annual): USD 49.15MUnknown
- Net income (annual): USD 16.52MUnknown
- Total liabilities (annual): USD 133.33MUnknown
- EPS (basic) (annual): USD-PER-SHARES 0Unknown
- Gross profit (annual): USD 205.6MUnknown
- Cost of revenue (annual): USD 70.66MUnknown
- Shareholders' equity (annual): USD 354.64MUnknown
- Operating income (annual): USD 11.04MUnknown
- Shares outstanding (annual): 50.62MUnknown
- Operating cash flow (annual): USD 51.91MUnknown
- Pre-tax income (annual): USD 17.38MUnknown
- Capex (annual): USD 27.16MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 0Unknown
- Total operating expenses (annual): USD 194.56MUnknown
- Total assets (annual): USD 487.97MUnknown
- Cash & equivalents (annual): USD 100.09MUnknown
- Revenue (annual): USD 276.26MUnknown
- Current assets (annual): USD 212.78MUnknown
- Cash & equivalents (annual): USD 74.52MUnknown
- Total liabilities (annual): USD 140.75MUnknown
- Net income (annual): USD 10.36MUnknown
- Pre-tax income (annual): USD 10.51MUnknown